San Francisco, CA Clinical Trials Report — June 2026

For San Franciscans considering participation in clinical research, June 2026 presents a critical window for numerous studies nearing their enrollment deadlines. Across San Francisco, CA, a total of 1,176 clinical trials are currently recruiting across 407 research facilities. However, 66 of these trials are slated to close within the next 90 days, making prompt action essential for interested individuals.

This urgency is particularly relevant for healthy volunteers, as 18 of these rapidly closing studies are still actively seeking participants without specific health conditions. These trials offer a chance to contribute to medical advancements before their enrollment windows close.

Impending Deadlines for Key Health Areas

Patients managing specific health conditions also face impending deadlines to join research. Trials focused on various cancers and other conditions are among those with limited time remaining for enrollment. Conditions with trials closing soon include:

• Cancer (3 trials)
• Ovarian cancer (2 trials)
• Endometrial cancer (2 trials)
• Gastroesophageal junction (GEJ) cancer (2 trials)
• Solid tumor (2 trials)
• Prostate cancer (2 trials)
• Lupus nephritis (2 trials)
• Cervical cancer (2 trials)
• Fallopian tube cancer (2 trials)
• Gastric cancer (2 trials)

New Research Opportunities Emerge

This month, San Francisco saw the opening of 17 new clinical trials, a decrease from the 28 trials that launched in May 2026. This trend continues a recent decline, with the 6-month trend showing a drop from 29 new trials in May to 17 in June.

June brings several notable new trials to San Francisco, including studies from major sponsors and local institutions. These trials offer participants the chance to engage with cutting-edge treatments and diagnostic approaches across a range of health challenges.

• Bayer is sponsoring NCT07625215, "A Study to Test How Well BAY 3670549 Works and How Safe it is in Patients With Atrial Fibrillation." This Phase 2 study aims for 360 participants to evaluate the efficacy, safety, tolerability, and pharmacokinetics of BAY 3670549 compared to a placebo in individuals with atrial fibrillation.
• The University of Florida is leading NCT07670650, the "PRISE Study" (Personalized Response and Immunologic Surveillance of Endogenous C-Peptide Preservation in New, Recent, and Established Onset Type 1 Diabetes Treated With Human Anti-Thymocyte Globulin [h-ATG]). This Phase 3, multicenter, randomized, double-blind, placebo-controlled study will evaluate the efficacy, safety, and tolerability of SAB-142 in participants aged 5 to 40 years with Stage 3 type 1 diabetes.
• The University of California, San Francisco is sponsoring NCT07661498, "Indomethacin for Biliary ERCP Patients." This Phase 4 randomized clinical trial aims for 860 participants to evaluate the efficacy of rectal indomethacin in preventing post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis in patients with a history of prior biliary sphincterotomy.
• Also from the University of California, San Francisco, NCT07629167, "Isotretinoin vs. Doxycycline for Acneiform Rash in Patients Receiving Drugs That Target the MAPK Pathway," is a Phase 2 study with 50 participants. It tests the efficacy of isotretinoin versus doxycycline in treating acneiform rash caused by certain tumor-directed therapies.
• The University of British Columbia is sponsoring NCT07629154, "Smart Discharges for Older Children." This observational multi-country cohort study aims for 4,000 participants to build algorithms that can identify children between 5 and 16 years of age admitted for proven or suspected sepsis who are at risk of mortality after discharge in East Africa.

New trials this month are exploring a range of conditions, with the most frequent being acneiform eruptions (1 trial), advanced solid tumor (1 trial), atrial fibrillation (1 trial), and bladder cancer (1 trial). Drug trials account for 5 of the new studies, alongside 5 behavioral studies, 2 procedure trials, and 1 device trial. The remaining 8 new trials are categorized as "OTHER." The University of California, San Francisco is a prominent sponsor, initiating 10 of the new trials.

Opportunities for Healthy Volunteers

For individuals without a specific medical condition, there are significant opportunities to contribute to research. Of the 17 new trials launched this month, 2 are actively seeking healthy volunteers. Across San Francisco, a total of 154 clinical trials are currently recruiting healthy participants, providing numerous avenues for those interested in supporting medical research.

San Francisco's Leading Research Facilities

San Francisco is home to some of the nation's leading research institutions, which consistently run a high volume of clinical trials. These facilities are key destinations for individuals seeking to participate in medical research:

• University of California, San Francisco (256 trials)
• University of California San Francisco (153 trials)
• UCSF Medical Center-Mission Bay (42 trials)
• Kaiser Permanente-San Francisco (39 trials)
• UCSF (31 trials)
• Research Site (26 trials)
• California Pacific Medical Center-Pacific Campus (25 trials)
• UCSF Helen Diller Family Comprehensive Cancer Center (25 trials)
• Zuckerberg San Francisco General Hospital (22 trials)
• University of California (21 trials)
• UCSF Medical Center (16 trials)
• University of California, San Francisco (UCSF) (15 trials)

These institutions, particularly the various branches of the University of California, San Francisco, offer a broad spectrum of research, making them central hubs for clinical trial participation in the city.

Broadening Your Search: Nearby Options

While San Francisco offers a vast array of clinical trial opportunities, individuals may also find options in nearby communities within California. Cities with active trials include Los Angeles (31 trials), San Diego (16 trials), Palo Alto (10 trials), La Jolla (9 trials), Stanford (7 trials), Sacramento (6 trials), Duarte (6 trials), and Walnut Creek (6 trials).

Participation in clinical trials is open to a diverse range of individuals. Of the 17 new trials launched this month, 12 include older adults, ensuring that senior populations have ample opportunity to contribute to medical science. Additionally, 5 new trials include children. Academic institutions continue to play a vital role in San Francisco's research ecosystem, with the University of California, San Francisco sponsoring the majority of new studies this month. Industry sponsors like Bayer are also driving significant research efforts.

As we move through June, San Francisco's robust research community will continue to drive medical innovation, offering diverse opportunities for individuals to contribute to the future of healthcare, particularly for those who act quickly on trials with impending deadlines.